Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Aikido Pharma Inc.

Viveve Medical

Biotech penny stocks are heating up right now, here's three to watch The post Are Biotech Penny Stocks Worth Buying? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Biotech Penny Stocks Worth Buying? Check These 3 Out

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

Ampio Pharmaceuticals Inc

CASI Pharmaceuticals

ConforMIS

AB Corporate Bond ETF

Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks For Your Biotech Watch List In September 2021

Atossa Genetics

Mind Medicine MindMed

PharmaCyte Biotech

Sesen Bio Inc.

VBI Vaccines

vTv Therapeutics

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace.

7 Penny Stocks Waiting on The FDA for Rocket Fuel

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound?

AstraZeneca

Biogen

Denali Therapeutics

Eli Lilly

Morphosys AG - ADR

Pfizer

Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be the most expensive of the pair with a market cap of $6.4 billion, while Clovis is far more digestible with a market value of only $567 million.

Biotech Takeovers Moved at Snail's Pace in 2nd Quarter

BEST Inc - ADR

SmileDirectClub

Exela Technologies

Short squeeze penny stocks are some of the most-searched for in the stock market today. The post Most Shorted Penny Stocks To Buy Today?

Most Shorted Penny Stocks To Buy Today? 4 To Watch As AMC Stock Pops

Shares of the biotech that focuses on oncology drugs climbed more than 12% during the week.

Why Clovis Oncology Shares Got a Bump This Week

Vinco Ventures

Kala Pharmaceuticals

Meta Materials

The SPRT stock breakout has shed light on other short-squeeze penny stocks The post 4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) to renew its previously established ATM facility under which it may offer and sell, from time to time, additional shares of its common stock having an aggregate offering price of up to $125,000,000 through an “at-the-market” equity offering program (the “ATM Program”). The timing and amount of any sales will be de

Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program

Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.

Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2021 Results - Earnings Call Transcript

Clovis (CLVS) delivered earnings and revenue surprises of -7.02% and -9.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2021, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year. “While these are obviously complicated times, I'm encouraged that, based on the data available to us, we have maintained our US market share for Rubraca and achieved meaningful growth in Europe in the second-line maintenance ovarian

Clovis Oncology Announces Second Quarter 2021 Operating Results

Clovis: Compelling With Upcoming Catalysts

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company's results in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for

Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today. “I am very pleased to welcome Dr. Ronit Simantov to the Clovis Oncology Board of Directors, as she brings a wealth of expertise in oncology research and drug development to the role,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Dr. Simantov's extensive background and experience will support Clovis' key strateg

Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

Clovis Oncology Inc. (NASDAQ: CLVS) shares gapped up Monday morning but have since fallen back to trading down on the day. There looks to be no company news acting as a catalyst that moved the share price, but likely the stock moved as retail traders pushed it.

What's Going On With Clovis Oncology Stock?

BOULDER, Colo.--(BUSINESS WIRE)--Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine

Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP), is now open at the O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham (UAB). The O'Neal Comprehensive Cancer Center at UAB is among the nation's leading cancer research institutions and one of only

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Atomera

Arcimoto

LifeMD 

Pubmatic

Root

Washington Prime Group

Looking for meme stocks to buy? These seven stocks, which are seeing increased price momentum, deserve your attention.

7 Best Meme Stocks to Buy Now Before They're Trending on Reddit

When future promise meets hype, it's hard to deny the potential.

2 Great Reasons to Buy This Cancer Treatment Stock Now

The biotech is getting the sort of attention that its short-sellers would rather avoid.

Here's Why Wall Street Is Betting Against Clovis Oncology

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) (the “Company”) today announced partial results and the partial adjournment of its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The Company adjourned the Annual Meeting solely with respect to Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 28, 2021 (as supplemented, “Proxy Statement”). Proposal 2 is a proposal to amend the Company's Amended and Re

News for Clovis Oncology Stock (CLVS)